CMS Throws a Gala to Celebrate Its SGX Encore, Promising to “Globalize” Pharma While Everyone Else Does the Math on Margins

On July 15, 2025, China Medical System Holdings Limited marked its secondary listing on the Singapore Exchange with a forum-dinner hybrid at its gleaming Tuas CDMO plant, because nothing says capital-market discipline like canapés beside stainless steel reactors.

About 150 representatives from government, pharma multinationals, biotech hopefuls, investors and pharma KOLs dutifully turned up to debate how to sell more drugs, faster, across Southeast Asia, the Middle East and every other “emerging” market investors suddenly remember exists when Western growth stalls.

Speakers from SGX, Singapore’s Economic Development Board, CGS International Securities, L.E.K. Consulting and A*STAR laid out the familiar trilogy of incentives, streamlined rules and capital access, with SGX’s Caihan Chia declaring the bourse increasingly attractive to Chinese issuers thanks to lighter friction and friendlier tax nudges.

“The successful listing of CMS showcases the growing interest among Chinese companies in the Singapore market,” Chia said, framing the deal as both validation for SGX and a springboard for CMS into Southeast Asia’s fragmented but fast-growing healthcare spend.

IQVIA data helpfully reminded the room why everyone is here: by 2028, Asia-Pacific, India, Africa and the Middle East, and Latin America together could be a USD 336 billion to USD 384 billion pharma market, which is suddenly comparable to Western Europe, and definitely not something investors were ignoring five years ago.

Singapore, with its predictable rule of law, deep capital pools and ability to host both roadshows and reactors, is positioning itself as the region’s clean room for cross-border pharma finance.

CMS, which insists it is no longer just “China’s largest CSO,” rolled out its dual-hub narrative: China for scale and speed, Singapore for global polish and investor access.

Chairman and CEO Lam Kong pitched “New CMS, New Ascent,” a three-engine strategy—product innovation, commercial transformation and international expansion—that he says is already delivering a durable second growth curve.

The company claims nearly 40 first-in-class or best-in-class drug candidates via licensing, partnerships and in-house R&D, with five already approved in China and in broad clinical use, while it doubles down on cardio-cerebrovascular, gastroenterology, ophthalmology and skin health to keep cash flows less cyclical.

Dermavon, its skin health arm, was spotlighted as a niche leader marching toward a Hong Kong spin-off, because nothing accelerates value creation like giving investors another ticker to argue about.

On globalization, CMS talked up its “bring in” and “move outward” two-way playbook, using Singapore to knit together R&D, manufacturing, commercialization and investment into something that resembles a multinational’s operating model, at least on the slides.

PharmaGend, its Tuas-based CMO/CDMO founded in 2023, was cast as Southeast Asia’s future production workhorse, already FDA and HSA certified for tablets and capsules, with injections, ointments and nasal sprays on the expansion roadmap.

Rxilient, established in 2021, said it has filed nearly 20 drug and device applications across Southeast Asia, the Middle East, Hong Kong, Macao and Taiwan, betting on dermatology, ophthalmology, oncology, autoimmune and CNS indications to turn regulatory approvals into real revenue.

CMS R&D, set up in Singapore in 2024, is pushing more than 10 early-stage programs, aiming to wed “China speed” to global standards, a phrase that sounds great in keynotes and terrifying in compliance departments.

HiGend, launched this year as a hub-and-spoke incubator, wants to industrialize early-stage biopharma creation by piping Chinese innovation into global trials and commercialization tracks.

Three panel discussions tried to answer the only question that matters: can Chinese innovators really scale outside the U.S. and Europe without getting swallowed by regulatory heterogeneity, pricing caps and a patchwork of distributors.

Executives dissected case studies like Stulln eye drops and ruxolitinib cream, arguing that clinical value plus omnichannel commercialization can still win in China and be ported to Southeast Asia if you own your sales muscle and data.

Others noted that Chinese drugmakers have racked up over USD 10 billion in upfront license-out payments in the past three years, mostly to the West, but the next growth burst could come from emerging markets that together house 1.8 billion people but spend a fraction of Western peers on healthcare.

Investment bankers and fund managers warned that most Chinese firms are still stuck in the “isolated breakthrough” phase, cashing single licensing checks rather than building repeatable, global operating systems.

To get past that plateau, they argued, companies will need full-stack internationalization—manufacturing, R&D, clinical, regulatory and commercialization—so they can convert episodic deal revenue into durable brand equity and pricing power.

CMS clearly thinks its China–Singapore lattice is that template, promising a closed loop of R&D, manufacturing, commercialization and investment that it says can be cloned across Southeast Asia and beyond.

Skeptics will point out that Southeast Asia’s six biggest economies are still dominated by out-of-pocket spending, generics and chaotic distribution, which makes “scalable” a generous adjective.

CMS counters that localized manufacturing, stronger in-market sales teams and smarter licensing will tilt the odds.

The applause lines faded with the stage lights, but the thesis held: emerging markets are where the volume is, Western Europe is where the benchmarks are, and Singapore is where you pitch both.

Whether CMS’s second growth curve bends up or flatlines will depend less on dinners in Tuas and more on how fast those nearly 40 pipeline assets clear regulators, find payers and prove clinical value in markets that are allergic to premium pricing.

For now, SGX gets another Chinese healthcare listing to market, CMS gets a new investor base to court, and everyone else gets one more case study to cite at the next “globalization” forum.